The Diabetes Shared Care Program and Risks of Cardiovascular Events in Type 2 Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 19.9K citations

Metabolic Syndrome, Diabetes Management, Insulin Management +9

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

Metabolic Syndrome, Diabetes Management, Diabetes Epidemiology +10

Standards of Medical Care in Diabetes—2014

Diabetes Care · 2013 · 4.5K citations · Full text

Diabetes Management, Health Policy, Diabetes +2

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Diabetes Management, Cardiovascular Disease, Health Policy +10

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

Open-label Trial, Diabetes Management, Cardiovascular Disease +10